# Ranibizumab for the Inhibition of Neovascularization in Pterygia

> **NCT00768963** · PHASE1 · COMPLETED · sponsor: **University of Miami** · enrollment: 10 (actual)

## Conditions studied

- Pterygium

## Interventions

- **DRUG:** ranibizumab
- **DRUG:** ranibizumab

## Key facts

- **NCT ID:** NCT00768963
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2011-11
- **Final completion:** 2012-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00768963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00768963, "Ranibizumab for the Inhibition of Neovascularization in Pterygia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00768963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*